Drugs / HRV Liquid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02141204 | Feb → Dec 2019 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2010-05-07 | GlaxoSmithKline | Results GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines gsk.com ↗
GSK presented data from investigations conducted since the finding of material from PCV-1 in Rotarix ® (Rotavirus Vaccine, Live, Oral). |
| 2009-11-29 | GlaxoSmithKline | Regulatory Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan gsk.com ↗
GlaxoSmithKline (GSK) announced today that it has filed its vaccine for the prevention of rotavirus gastroenteritis (approved as Rotarix ® in a number of countries outside of Japan). |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRV Liquid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02141204 ↗ |
| Known as | Rotarix | “Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants” NCT02141204 ↗ |
| Modality | Vaccine | “Oral Live Attenuated Human Rotavirus (HRV) Vaccine” NCT02141204 ↗ |
| Route | Oral | “Two doses administered orally according to a 0, 1-month schedule.” NCT02141204 ↗ |